Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giuseppe Lopalco

Showing results (141-150 of 221) with videos related to

Pageof 23
Sort By:
Clinical and Experimental Rheumatology|July 25, 2024
Effectiveness of ixekizumab over 24 months in different clinical scenarios in psoriatic arthritis: results from the Gruppo Italiano Studio Early Arthritis multicentric prospective registryMaria Sole Chimenti, Mauro Fatica, Marco Fornaro, et al.
Internal and Emergency Medicine|April 9, 2021
Clinical profile and evolution of patients with juvenile-onset Behçet's syndrome over a 25-year period: insights from the AIDA networkJurgen Sota, Donato Rigante, Giuseppe Lopalco, et al.
Frontiers in Medicine|March 26, 2024
Retention rate of biologic and targeted synthetic anti-rheumatic drugs in elderly rheumatoid arthritis patients: data from GISEA registryAndreina Manfredi, Marco Fornaro, Chiara Bazzani, et al.
Clinical and Experimental Rheumatology|January 27, 2022
Retention rate of IL-1 inhibitors in Schnitzler's syndromeFrancesca Crisafulli, Antonio Vitale, Paolo Airò, et al.
RMD Open|March 24, 2026
Comparative effectiveness and predictors of remission between adalimumab and ixekizumab in patients with psoriatic arthritis: findings from the 'AIRE' multicentre studyValentino Paci, Alen Zabotti, Alessandro Fontanarosa, et al.
Annals of the Rheumatic Diseases|December 13, 2025
ChatGPT vs rheumatologists: cross-sectional study on accuracy and patient perception of AI-generated information for psoriatic arthritisGiulio Forte, Daniele Mauro, Maura Raimondi, et al.
Frontiers in Pharmacology|January 24, 2019
Drug Retention Rate and Predictive Factors of Drug Survival for Interleukin-1 Inhibitors in Systemic Juvenile Idiopathic ArthritisJurgen Sota, Antonella Insalaco, Rolando Cimaz, et al.
Journal of the American Geriatrics Society|September 9, 2024
Recurrent pericarditis in older adults: Clinical and laboratory features and outcomeEmanuele Bizzi, Francesco Cavaleri, Ruggiero Mascolo, et al.
RMD Open|July 25, 2020
Development and preliminary validation of the Behçet's syndrome Overall Damage Index (BODI)Matteo Piga, Alberto Floris, Gerard Espinosa, et al.
International Journal of Molecular Sciences|May 27, 2023
Serum Interleukin-36 α as a Candidate Biomarker to Distinguish Behçet's Syndrome and Psoriatic ArthritisAlessandra Bettiol, Filippo Fagni, Irene Mattioli, et al.
Pageof 23

Showing results (141-150 of 221) with videos related to

Sort By:
Pageof 23
Clinical and Experimental Rheumatology|July 25, 2024
Effectiveness of ixekizumab over 24 months in different clinical scenarios in psoriatic arthritis: results from the Gruppo Italiano Studio Early Arthritis multicentric prospective registryMaria Sole Chimenti, Mauro Fatica, Marco Fornaro, et al.
Internal and Emergency Medicine|April 9, 2021
Clinical profile and evolution of patients with juvenile-onset Behçet's syndrome over a 25-year period: insights from the AIDA networkJurgen Sota, Donato Rigante, Giuseppe Lopalco, et al.
Frontiers in Medicine|March 26, 2024
Retention rate of biologic and targeted synthetic anti-rheumatic drugs in elderly rheumatoid arthritis patients: data from GISEA registryAndreina Manfredi, Marco Fornaro, Chiara Bazzani, et al.
Clinical and Experimental Rheumatology|January 27, 2022
Retention rate of IL-1 inhibitors in Schnitzler's syndromeFrancesca Crisafulli, Antonio Vitale, Paolo Airò, et al.
RMD Open|March 24, 2026
Comparative effectiveness and predictors of remission between adalimumab and ixekizumab in patients with psoriatic arthritis: findings from the 'AIRE' multicentre studyValentino Paci, Alen Zabotti, Alessandro Fontanarosa, et al.
Annals of the Rheumatic Diseases|December 13, 2025
ChatGPT vs rheumatologists: cross-sectional study on accuracy and patient perception of AI-generated information for psoriatic arthritisGiulio Forte, Daniele Mauro, Maura Raimondi, et al.
Frontiers in Pharmacology|January 24, 2019
Drug Retention Rate and Predictive Factors of Drug Survival for Interleukin-1 Inhibitors in Systemic Juvenile Idiopathic ArthritisJurgen Sota, Antonella Insalaco, Rolando Cimaz, et al.
Journal of the American Geriatrics Society|September 9, 2024
Recurrent pericarditis in older adults: Clinical and laboratory features and outcomeEmanuele Bizzi, Francesco Cavaleri, Ruggiero Mascolo, et al.
RMD Open|July 25, 2020
Development and preliminary validation of the Behçet's syndrome Overall Damage Index (BODI)Matteo Piga, Alberto Floris, Gerard Espinosa, et al.
International Journal of Molecular Sciences|May 27, 2023
Serum Interleukin-36 α as a Candidate Biomarker to Distinguish Behçet's Syndrome and Psoriatic ArthritisAlessandra Bettiol, Filippo Fagni, Irene Mattioli, et al.
Pageof 23